Fusion Pharma

New heights in CML therapy

Improving the efficacy and safety in the treatment of resistant forms of chronic myelogenous leukemia, including the variant with T315I mutation

Mutation T315I under sight

Efficacy against clones of CML tumor cells with T315I mutation in the proto-oncogene BCR-ABL

Suppression of the emergence of resistance

Suppression of the emergence of resistant forms of CML in experiments with directed mutagenesis of CML tumor cells

When resistant to two or more Abl inhibitors

Investigating efficacy and safety in patients resistant to at least two Abl inhibitors

Advanced phases of CML

Investigating the efficacy in the accelerated phase and blast crisis and potentials in the therapy of Ph + acute lymphoblastic leukemia

For Patients

When deciding to participate in the trial, please, contact the study coordinators of one of the two clinical sites directly to see if you are eligible for the trial: A multicenter, open label cohort Phase 1 dose escalation study to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PF-114 mesylate for oral administration in adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), which is resistant to the 2-nd generation Bcr-Abl inhibitors or has T315I mutation in the BCR-ABL gene. The information on the Study is listed on registry and results database of publicly and privately supported clinical studies of human participants conducted around the world — the ClinicalTrials.gov

Please, see the Informed Consent Form to participate in the Clinical Trial.

DOWNLOAD

National Research Center for Hematology

Russia, 125 167, Moscow, Novii Zikovskii pr., 4

Principal Investigator:
Prof. DMSci Anna Turkina — Head of Myeloproliferative diseases
Clinical Study Coordinator:
Oleg Shuhov MD, PhD

Federal Almazov North-West Medical Research Centre

Russia, 197 341, St. Petersburg, Akkuratova st., 2

Principal Investigator:
Elza Lomaia MD, PhD, — lead scientist of Onco-hematology Department

Moscow City Centre of Hematology based on City Hospital named by S.Botkin

5, 2-nd Botkin's lane, build. 17, entrance 3
125284 Moscow

Principal Investigator:
Prof. DMSci Olga Vinogradova — Head of Moscow City Centre of Hematology